EryDex shows Phase II promise for rare disease ataxia telangiectasia
This article was originally published in Scrip
Executive Summary
Privately-held Italian biotech firm EryDel has reported positive Phase II results for EryDex (dexamethasone sodium phosphate, intra-erythrocyte), its treatment for ataxia telangiectasia (AT).